Synta Pharmaceuticals announced that the FDA has granted Fast Track designation to ganetespib to improve overall survival when administered in combination with docetaxel for the treatment of patients with metastatic non-small lung adenocarcinoma who have progressed following one prior chemotherapy regimen.

RELATED: Non-Small Cell Lung Cancer Treatments Chart

Ganetespib is a selective inhibitor of heat shock protein 90 (Hsp90), a molecular chaperone which controls the folding and activation of a number of client proteins that drive tumor development and progression.

Ganetespib is being evaluated for the treatment of non-small cell lung adenocarcinoma in the GALAXY program, consisting of  two randomized trials comparing the combination of ganetespib and docetaxel vs. docetaxel alone in patients with Stage IIIB/IV NSCLC who have received one prior systemic therapy: a 300-patient Phase 2b/3 trial (GALAXY-1) to determine the patient population most likely to derive benefit from ganetespib, and a 500-patient confirmatory Phase 3 trial (GALAXY-2).

For more information call (781) 274-8200 or visit